Summary
Pfizer Inc. filed this 8-K report on April 28, 2014, primarily to disclose its prior and ongoing engagement with AstraZeneca plc regarding a potential merger. The company confirmed it had submitted a preliminary, non-binding proposal to AstraZeneca, which was subsequently declined after initial discussions ceased in January 2014. In light of recent market developments, Pfizer re-engaged AstraZeneca on April 26, 2014, but the company once again declined to enter into discussions. Pfizer stated it is currently considering its options with respect to AstraZeneca.
Key Highlights
- 1Pfizer Inc. publicly disclosed its unsolicited, non-binding proposal to merge with AstraZeneca plc.
- 2Initial discussions between Pfizer and AstraZeneca regarding the merger proposal occurred in early 2014 and were discontinued in January 2014.
- 3Pfizer re-approached AstraZeneca on April 26, 2014, to resume merger discussions, but AstraZeneca declined to engage.
- 4Pfizer is currently evaluating its strategic options concerning AstraZeneca.
- 5The filing includes various communications such as an announcement, internal and external letters, an investor presentation, and CEO video interviews related to the potential transaction.